Unprecedented Set of New Clinical Trials Using MolecuLight Wound Imaging Platform Demonstrates Improvement in Clinical Decision Making and Patient Outcomes
TORONTO and LAS VEGAS, Nov. 2, 2023 /PRNewswire/ — MolecuLight Inc., a leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that MolecuLight data will be presented in 12 posters and clinical presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2023. Results to be presented include new data from recent research using the MolecuLight device in more than 1,500 patients. The international conference will be held November 2-5, 2023 in Las Vegas, Nevada, and is one of the largest multidisciplinary gatherings of wound care professionals in the world.
“We are proud to once again see abundant and consistent favorable results presented by users of the MolecuLight imaging platform at this week’s SAWC conference,” said Anil Amlani, CEO of MolecuLight. “The volume of our clinical evidence continues to grow and confirms that MolecuLight improves healing outcomes. Our devices inform the appropriate use of antibiotics and help empower patients during the treatment and recovery of their wounds. We are especially encouraged by the impact of our clinical outcomes on vulnerable patient populations experiencing healthcare inequalities. Our device has proven to be an equitable diagnostic tool that delivers quality results to patients of all skin tones. This sets us apart and makes us a part of the solution, and we couldn’t be more proud of it.”
“Good wound hygiene is a game-changer in taking wound care to the next level and improving outcomes. I always say you have to clean properly, but we can only clean what we see. MolecuLight is an objective tool that, for the first time, allows healthcare personnel to visualize in real time and more effectively eliminate bacterial load that would otherwise be invisible to the naked eye,” said Dot Weir, RN, CWON, CWS, nurse practitioner. specialist in wound care at the Center for Wound Healing and Hyperbaric Medicine at Saratoga Hospital in Saratoga Springs, New York, and co-chair of the Symposium on Advanced Wound Care (SAWC). Dot Ella will be participating in a hands-on pre-conference workshop showing how MolecuLight can be used to guide and improve wound hygiene practices. “We can and must do better. The MolecuLight device is backed by evidence, is equitable for all patients, and is instrumental in the care of each and every patient who walks through our doors. This incredible wearable technology is revolutionizing the way we that we clean the wounds. I can’t imagine the highest quality of care without it.
Clinical presentations and posters with MolecuLight i:X and DX from SAWC Fall 2023 are as follows: CLINICAL PRESENTATIONS
Saturday, November 4, 2023, 5:00 PM – 6:00 PM PDT, Julius 7-10 Downloadposter
b) CLINICAL POSTERS
Download poster
Download poster
Download poster
In addition to posters and clinical presentations at SAWC Fall 2023, MolecuLight i:X® and DX™ imaging devices will be available for demonstration at the exhibitor
MolecuLight i:X® and DX™ are the only imaging devices for real-time detection of high bacterial load in wounds that are FDA-cleared, EC-approved, and Health Canada approved. . With unrivaled clinical evidence including over 80 peer-reviewed publications and 2,600 patients, they are used by leading wound care centers around the world.
About MolecuLight Inc.
MolecuLight Inc. is a privately held medical imaging company that has developed and commercializes its proprietary fluorescent imaging platform technology in multiple clinical markets. The MolecuLight suite of commercial devices, which includes the MolecuLight i:X® and DX™ fluorescence imaging systems and accessories, are portable point-of-care imaging devices for real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway that includes two CPT® codes for the physician’s work to perform “fluorescence imaging for the presence, location and load of bacteria” and the facility’s payment for the Hospital Outpatient Department (HOPD) and the Ambulatory Surgical Center (ASC) through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology to other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.
Rob Sandler, director de Marketing, MolecuLight Inc., T. 1.647.362.4684, rsandler@moleculight.com, www.moleculight.com
Photo – https://mma.prnewswire.com/media/2264598…
Photo – https://mma.prnewswire.com/media/2264599…
View original content: https://www.prnewswire.com/news-releases/se-presentaran-12-posteres-y-presentaciones-de-moleculight-en-la-conferencia-sawc-fall-2023-301976244.html
